NewAmsterdam Pharma (NAMS) Gains from Investment Securities (2022 - 2026)

NewAmsterdam Pharma has disclosed Gains from Investment Securities across 5 years of filings, most recently posting $54.6 million for Q1 2026.

• Gains from Investment Securities for Q1 2026 came in at $54.6 million, up 215.61% year-over-year; the trailing twelve-month figure through Mar 2026 was $128.1 million (up 181.39% YoY), and the FY2025 annual result was $20.6 million, up 8.39% from the prior year.
• Gains from Investment Securities came in at $54.6 million for Q1 2026 at NewAmsterdam Pharma, up from $29.6 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $54.6 million in Q1 2026 to a low of $63961.0 in Q3 2025.
• The 5-year median for Gains from Investment Securities is $11.4 million (2022), against an average of $15.9 million.
• Across the five-year window, Gains from Investment Securities surged 1161.31% in 2024 and plunged 99.68% in 2025, its largest moves.
• NewAmsterdam Pharma's Gains from Investment Securities stood at $11.4 million in 2022, then sank by 85.93% to $1.6 million in 2023, then surged by 1564.88% to $26.6 million in 2024, then advanced by 11.12% to $29.6 million in 2025, then jumped by 84.46% to $54.6 million in 2026.
• The last three Gains from Investment Securities figures came in at $54.6 million (Q1 2026), $29.6 million (Q4 2025), and $63961.0 (Q3 2025), per Business Quant data.